Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Ju Hee Lee  (Lee JH) 8 Articles
Drug/Regimen
Article image
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
Ji Hye Han, Kyong Hye Joung, Jun Choul Lee, Ok Soon Kim, Sorim Choung, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Bon Jeong Ku, Hyun Jin Kim
Diabetes Metab J. 2024;48(1):112-121.   Published online January 3, 2024
DOI: https://doi.org/10.4093/dmj.2022.0402
  • 3,090 View
  • 292 Download
  • 1 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Type 2 diabetes mellitus (T2DM) induces endothelial dysfunction and inflammation, which are the main factors for atherosclerosis and cardiovascular disease. The present study aimed to compare the effects of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on lipid profile, insulin sensitivity, and vascular inflammatory response in patients with T2DM.
Methods
A total of 101 patients with T2DM and dyslipidemia were randomized to either rosuvastatin monotherapy (5 mg/day, n=47) or rosuvastatin/ezetimibe combination therapy (5 mg/10 mg/day, n=45) and treated for 12 weeks. Serum lipids, glucose, insulin, soluble intercellular adhesion molecule-1 (sICAM-1), and peroxiredoxin 4 (PRDX4) levels were determined before and after 12 weeks of treatment.
Results
The reduction in low density lipoprotein cholesterol (LDL-C) by more than 50% from baseline after treatment was more in the combination therapy group. The serum sICAM-1 levels increased significantly in both groups, but there was no difference between the two groups. The significant changes in homeostasis model assessment of insulin resistance (HOMA-IR) and PRDX4 were confirmed only in the subgroup in which LDL-C was reduced by 50% or more in the combination therapy group. However, after adjusting for diabetes mellitus duration and hypertension, the changes in HOMA-IR and PRDX4 were not significant between the two groups.
Conclusion
Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.

Citations

Citations to this article as recorded by  
  • Combining Ezetimibe and Rosuvastatin: Impacts on Insulin Sensitivity and Vascular Inflammation in Patients with Type 2 Diabetes Mellitus
    Eun Roh
    Diabetes & Metabolism Journal.2024; 48(1): 55.     CrossRef
  • Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?
    Il Rae Park, Jun Sung Moon
    Diabetes & Metabolism Journal.2024; 48(3): 387.     CrossRef
  • A Comparison of Rosuvastatin Monotherapy and Rosuvastatin Plus Ezetimibe Combination Therapy in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Samuel K Dadzie, Godfrey Tabowei, Mandeep Kaur, Saeed Ahmed, Aayushi Thakur, Khaldoun Khreis, Monika Bai, Adil Amin
    Cureus.2024;[Epub]     CrossRef
Others
Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance
Yea Eun Kang, Ji Min Kim, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
Diabetes Metab J. 2019;43(3):368-376.   Published online October 23, 2018
DOI: https://doi.org/10.4093/dmj.2018.0066
  • 5,292 View
  • 77 Download
  • 6 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   
Background

Recent in vivo studies indicated that R-spondin 1 (RSPO1) regulates food intake and increases insulin secretion, but its role in humans remains unknown. This study investigated the association between serum levels of RSPO1 and diverse metabolic parameters in humans.

Methods

The study population consisted of 43 subjects with newly diagnosed diabetes mellitus, and 79 non-diabetic participants. Serum levels of RSPO1 were measured using the enzyme-linked immunosorbent assay. The relationships between circulating RSPO1 and diverse metabolic parameters were analyzed.

Results

Circulating RSPO1 levels increased to a greater extent in the obese group than in the lean group. Moreover, serum levels of RSPO1 were higher in the insulin-resistant group than in the insulin-sensitive group. Serum levels of RSPO1 were significantly correlated with a range of metabolic parameters including body mass index, fasting C-peptide, homeostasis model assessment of insulin resistance index, and lipid profile. Moreover, levels were significantly associated with insulin resistance and obesity in non-diabetic subjects.

Conclusion

This study demonstrated the association between serum levels of RSPO1 and a range of metabolic parameters in humans. Serum levels of RSPO1 are significantly related to obesity and insulin resistance, although the precise mechanisms remain unknown.

Citations

Citations to this article as recorded by  
  • Systems genetics analysis of human body fat distribution genes identifies adipocyte processes
    Jordan N Reed, Jiansheng Huang, Yong Li, Lijiang Ma, Dhanush Banka, Martin Wabitsch, Tianfang Wang, Wen Ding, Johan LM Björkegren, Mete Civelek
    Life Science Alliance.2024; 7(7): e202402603.     CrossRef
  • LGR4: A New Receptor Member in Endocrine and Metabolic Diseases
    Ningning Zhang, Mingyang Yuan, Jiqiu Wang
    Endocrine Reviews.2023; 44(4): 647.     CrossRef
  • R-Spondin1 and tumor necrosis factor-alpha in infertile women with polycystic ovary syndrome: relationships with insulin resistance and other parameters
    Tuğba GÜRBÜZ, Oya GÖKMEN, Asena AYAR MADENLİ, Berna DİLBAZ
    Journal of Health Sciences and Medicine.2023; 6(2): 449.     CrossRef
  • An early prediction model for type 2 diabetes mellitus based on genetic variants and nongenetic risk factors in a Han Chinese cohort
    Jinjin Li, Qun Ye, Hongxiao Jiao, Wanyao Wang, Kai Zhang, Chen Chen, Yuan Zhang, Shuzhi Feng, Ximo Wang, Yubao Chen, Huailin Gao, Fengjiang Wei, Wei-Dong Li
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Emerging Therapeutic Strategies for Attenuating Tubular EMT and Kidney Fibrosis by Targeting Wnt/β-Catenin Signaling
    Lichao Hu, Mengyuan Ding, Weichun He
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Does Serum R-Spondin-1 Play a Role in PCOS Pathophysiology?
    Osman BAŞPINAR, Yasin ŞİMŞEK, Derya KOÇER, Oğuzhan Sıtkı DİZDAR, Hatice KAYIŞ TOPALOĞLU
    Genel Tıp Dergisi.2022; 32(5): 490.     CrossRef
  • Silencing of RSPO1 mitigates obesity-related renal fibrosis in mice by deactivating Wnt/β-catenin pathway
    Xuesong Su, Guangyu Zhou, Mi Tian, Si Wu, Yanqiu Wang
    Experimental Cell Research.2021; 405(2): 112713.     CrossRef
  • Exosome miR‐27a‐3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma
    Xuehan Fan, Jingya Wang, Tingting Qin, Yujia Zhang, Wenting Liu, Kaiting Jiang, Dingzhi Huang
    Thoracic Cancer.2020; 11(6): 1453.     CrossRef
  • Integrative Analyses of Genes Associated with Subcutaneous Insulin Resistance
    Manoj Kumar Pujar, Basavaraj Vastrad, Chanabasayya Vastrad
    Biomolecules.2019; 9(2): 37.     CrossRef
Others
Serum Soluble Epidermal Growth Factor Receptor Level Increase in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
Ji Min Kim, Sorim Choung, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
Diabetes Metab J. 2018;42(4):343-347.   Published online May 2, 2018
DOI: https://doi.org/10.4093/dmj.2017.0082
  • 4,472 View
  • 50 Download
  • 6 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   

We analyzed circulating soluble epidermal growth factor receptor (sEGFR) levels in humans. Serum sEGFR levels were higher in subjects with newly diagnosed type 2 diabetes mellitus compared with controls. Serum sEGFR was positively correlated with glycosylated hemoglobin and serum glucose and negatively correlated with serum insulin and C-peptide levels.

Citations

Citations to this article as recorded by  
  • Increased serum extrachromosomal circular DNA SORBS1circle level is associated with insulin resistance in patients with newly diagnosed type 2 diabetes mellitus
    Xiang Kong, Shu-jun Wan, Tian-bing Chen, Lan Jiang, Yu-jie Xing, Ya-ping Bai, Qiang Hua, Xin-ming Yao, Yong-li Zhao, Hong-mei Zhang, De-guo Wang, Qing Su, Kun Lv
    Cellular & Molecular Biology Letters.2024;[Epub]     CrossRef
  • A Pilot Genome-Wide Association Study Identifies Novel Markers of Metabolic Syndrome in Patients with Psoriasis
    Seung-Min Oh, Su-Kang Kim, Hye-Jin Ahn, Ki-Heon Jeong
    Annals of Dermatology.2023; 35(4): 285.     CrossRef
  • Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor level in type 2 diabetes and hypercholesterolemia
    Jun Choul Lee, Kyong Hye Joung, Ji Min Kim, Seon Mee Kang, Hyun Jin Kim, Bon Jeong Ku
    Medicine.2022; 101(34): e30287.     CrossRef
  • Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects
    Mayu Kyohara, Jun Shirakawa, Tomoko Okuyama, Yu Togashi, Ryota Inoue, Jinghe Li, Daisuke Miyashita, Yasuo Terauchi
    Diabetology & Metabolic Syndrome.2020;[Epub]     CrossRef
  • Epidermal growth factor protects against myocardial ischaemia reperfusion injury through activating Nrf2 signalling pathway
    Jun Ma, Ge Jin
    Free Radical Research.2019; 53(3): 313.     CrossRef
Subjective Assessment of Diabetes Self-Care Correlates with Perceived Glycemic Control but not with Actual Glycemic Control
Jung Hun Ohn, Ju Hee Lee, Eun Shil Hong, Bo Kyung Koo, Sang Wan Kim, Ka Hee Yi, Min Kyong Moon
Diabetes Metab J. 2015;39(1):31-36.   Published online February 16, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.1.31
  • 3,673 View
  • 29 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFPubReader   
Background

We investigated whether patients' perceived glycemic control and self-reported diabetes self-care correlated with their actual glycemic control.

Methods

A survey was administered among patients with diabetes mellitus at an outpatient clinic with structured self-report questionnaires regarding perceived glycemic control and diabetes self-management. Actual glycemic control was defined as a change in glycated hemoglobin (A1C) or fasting plasma glucose (FPG) since the last clinic visit.

Results

Patients who perceived their glycemic control as "improved" actually showed a mild but significant decrease in the mean A1C (-0.1%, P=0.02), and those who perceived glycemic control as "aggravated" had a significant increase in the mean FPG (10.5 mg/dL or 0.59 mmol/L, P=0.04) compared to the "stationary" group. However, one-half of patients falsely predicted their actual glycemic control status. Subjective assessment of diabetes self-care efforts, such as adherence to a diet regimen or physical activity, correlated positively with perceived glycemic control but showed no association with actual glycemic control.

Conclusion

Patients should be encouraged to assess and monitor diabetes self-care more objectively to motivate behavioral modifications and improve their actual glycemic control.

Citations

Citations to this article as recorded by  
  • Social Networking Services-Based Communicative Care for Patients with Diabetes Mellitus in Korea
    Hun-Sung Kim, Yoo Jeong, Sun Baik, So Yang, Tong Kim, Hyunah Kim, Hyunyong Lee, Seung-Hwan Lee, Jae Cho, In-Young Choi, Kun-Ho Yoon
    Applied Clinical Informatics.2016; 07(03): 899.     CrossRef
GDF15 Is a Novel Biomarker for Impaired Fasting Glucose
Jun Hwa Hong, Hyo Kyun Chung, Hye Yoon Park, Kyong-Hye Joung, Ju Hee Lee, Jin Gyu Jung, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong
Diabetes Metab J. 2014;38(6):472-479.   Published online December 15, 2014
DOI: https://doi.org/10.4093/dmj.2014.38.6.472
  • 5,825 View
  • 79 Download
  • 69 Web of Science
  • 65 Crossref
AbstractAbstract PDFPubReader   
Background

Growth differentiation factor-15 (GDF15) is a protein that belongs to the transforming growth factor β superfamily. An elevated serum level of GDF15 was found to be associated with type 2 diabetes mellitus (T2DM). T2DM is an inflammatory disease that progresses from normal glucose tolerance (NGT) to impaired fasting glucose (IFG). Hence, we aimed to validate the relationship between GDF15 and IFG.

Methods

The participants were divided into the following three groups: NGT (n=137), IFG (n=29), and T2DM (n=75). The controls and T2DM outpatients visited the hospital for routine health check-ups. We used fasting blood glucose to detect IFG in nondiabetic patients. We checked the body mass index (BMI), C-reactive protein level, metabolic parameters, and fasting serum GDF15 level.

Results

Age, BMI, triglyceride, insulin, glucose, homeostatic model assessment-insulin resistance (HOMA-IR), and GDF15 levels were elevated in the IFG and T2DM groups compared to the NGT group. In the correlation analysis between metabolic parameters and GDF15, age and HOMA-IR had a significant positive correlation with GDF15 levels. GDF15 significantly discriminated between IFG and NGT, independent of age, BMI, and HOMA-IR. The serum levels of GDF15 were more elevated in men than in women. As a biomarker for IFG based on the receiver operating characteristic curve analysis, the cutoff value of GDF15 was 510 pg/mL in males and 400 pg/mL in females.

Conclusion

GDF15 had a positive correlation with IR independent of age and BMI, and the serum level of GDF15 was increased in the IFG and T2DM groups. GDF15 may be a novel biomarker for detecting IFG in nondiabetic patients.

Citations

Citations to this article as recorded by  
  • Effect of a 6-Week Carbohydrate-Reduced High-Protein Diet on Levels of FGF21 and GDF15 in People With Type 2 Diabetes
    Michael M Richter, Mads N Thomsen, Mads J Skytte, Sasha A S Kjeldsen, Amirsalar Samkani, Jan Frystyk, Faidon Magkos, Jens J Holst, Sten Madsbad, Thure Krarup, Steen B Haugaard, Nicolai J Wewer Albrechtsen
    Journal of the Endocrine Society.2024;[Epub]     CrossRef
  • Serum Growth Differentiation Factor 15 Levels Predict the Incidence of Frailty among Patients with Cardiometabolic Diseases
    Kazuhito Oba, Joji Ishikawa, Yoshiaki Tamura, Yasunori Fujita, Masafumi Ito, Ai Iizuka, Yoshinori Fujiwara, Remi Kodera, Kenji Toyoshima, Yuko Chiba, Masashi Tanaka, Atsushi Araki
    Gerontology.2024; 70(5): 517.     CrossRef
  • Growth differentiation factor 15 and malnutrition in older adults
    Nazanin Rostami, Blanca Fabre-Estremera, Antonio Buño-Soto, José R Banegas, Fernando Rodríguez-Artalejo, Rosario Ortolá
    The Journal of nutrition, health and aging.2024; 28(6): 100230.     CrossRef
  • Evaluation of the relation between subclinical systolic dysfunction defined by four-dimensional speckle-tracking echocardiography and growth differentiation factor-15 levels in patients with acromegaly
    Busra Firlatan, Ugur Nadir Karakulak, Vedat Hekimsoy, Burcin Gonul Iremli, Incilay Lay, Deniz Yuce, Selcuk Dagdelen, Giray Kabakci, Tomris Erbas
    Hormones.2024;[Epub]     CrossRef
  • Nausea, vomiting and conflict in pregnancy
    Bernard J Crespi
    Evolution, Medicine, and Public Health.2024; 12(1): 75.     CrossRef
  • Correlations between growth differentiation factor 15 (GDF-15) serum levels and gene polymorphism with type 2 diabetes mellitus
    Qiumei Liu, Lidong Qin, Yujian Liang, Min Xu, Junling Zhang, Xiaoting Mo, Xu Tang, Yufu Lu, Xuexiu Wang, Jiejing Cao, Chuwu Huang, Jiahui Rong, Kaisheng Teng, Linhai Zhao, Songju Wu, Lei Luo, Qinyi Guan, TianTian Zhang, Wenjia Jin, Jian Qin, Jiansheng Cai
    Heliyon.2024; 10(12): e33044.     CrossRef
  • Exploration of meteorin-like peptide (metrnl) predictors in type 2 diabetic patients: the potential role of irisin, and other biochemical parameters
    Yaser Khajebishak, Amir Hossein Faghfouri, Ali Soleimani, Sadra Madani, Laleh Payahoo
    Hormone Molecular Biology and Clinical Investigation.2023; 44(2): 127.     CrossRef
  • Relationship between meteorin-like peptide (Metrnl) serum levels and inflammatory cytokines, oxidative stress biomarkers and body composition parameters in type 2 diabetes patients
    Yaser Khajebishak, Sadra Madani, Amir Hossein Faghfouri, Ali Soleimani, Sara Ilaei, Said Peyrovi, Laleh Payahoo
    Nutrition & Food Science.2023; 53(5): 861.     CrossRef
  • Effects of acute exercise and exercise training on plasma GDF15 concentrations and associations with appetite and cardiometabolic health in individuals with overweight or obesity – A secondary analysis of a randomized controlled trial
    Jonas Salling Quist, Anders Bue Klein, Kristine Færch, Kristine Beaulieu, Mads Rosenkilde, Anne Sofie Gram, Anders Sjödin, Signe Torekov, Bente Stallknecht, Christoffer Clemmensen, Martin Bæk Blond
    Appetite.2023; 182: 106423.     CrossRef
  • Significant increase of serum extracellular vesicle-packaged growth differentiation factor 15 in type 2 diabetes mellitus: a cross-sectional study
    Wen Zhao, Xinwei Li, Xinxin Li, Lu Peng, Yu Li, Yunhui Du, Jianxun He, Yanwen Qin, Huina Zhang
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Association between growth differentiation factor 15 levels and gestational diabetes mellitus: A combined analysis
    Yi-Cheng Lu, Song-Liang Liu, Yu-Shan Zhang, Fei Liang, Xiao-Yan Zhu, Yue Xiao, Jing Wang, Cong Ding, Sudipta Banerjee, Jie-Yun Yin, Qiu-Ping Ma
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight
    Song-Yang Zhang, Kyla Bruce, Zahra Danaei, Rosa J.W. Li, Daniel R. Barros, Rachel Kuah, Yu-Mi Lim, Laura H. Mariani, David Z. Cherney, Jennifer F.M. Chiu, Heather N. Reich, Tony K.T. Lam
    Cell Metabolism.2023; 35(5): 875.     CrossRef
  • Growth differentiation factor 15 (GDF-15) in endocrinology
    Pedro Iglesias, Ramona A. Silvestre, Juan J. Díez
    Endocrine.2023; 81(3): 419.     CrossRef
  • Identification of biomarkers for glycaemic deterioration in type 2 diabetes
    Roderick C. Slieker, Louise A. Donnelly, Elina Akalestou, Livia Lopez-Noriega, Rana Melhem, Ayşim Güneş, Frederic Abou Azar, Alexander Efanov, Eleni Georgiadou, Hermine Muniangi-Muhitu, Mahsa Sheikh, Giuseppe N. Giordano, Mikael Åkerlund, Emma Ahlqvist, A
    Nature Communications.2023;[Epub]     CrossRef
  • Metabolic syndrome and Growth Differentiation Factor 15 in older adults
    Adrián Carballo-Casla, Esther García-Esquinas, Antonio Buño-Soto, Ellen A. Struijk, Esther López-García, Fernando Rodríguez-Artalejo, Rosario Ortolá
    GeroScience.2022; 44(2): 867.     CrossRef
  • Associations between GDF15 Levels and Pre-Diabetes in Non-Obese Subjects
    Hao-Chang Hung, Hung-Tsung Wu, Ching-Han Lin, Hsuan-Wen Chou, Horng-Yih Ou, Chih-Jen Chang
    Journal of Investigative Medicine.2022; 70(1): 79.     CrossRef
  • Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
    Dipayan Roy, Purvi Purohit, Anupama Modi, Manoj Khokhar, Ravindra Kumar Gayaprasad Shukla, Ramkaran Chaudhary, Shrimanjunath Sankanagoudar, Praveen Sharma
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Growth Differentiation Factor 15 Protects SH-SY5Y Cells From Rotenone-Induced Toxicity by Suppressing Mitochondrial Apoptosis
    Peizheng Li, Hongbo Lv, Bohan Zhang, Ruonan Duan, Xiufang Zhang, Pengfei Lin, Chengyuan Song, Yiming Liu
    Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
  • GDF-15 as a Therapeutic Target of Diabetic Complications Increases the Risk of Gallstone Disease: Mendelian Randomization and Polygenic Risk Score Analysis
    Lili Yu, Yajing Zhou, Lijuan Wang, Xuan Zhou, Jing Sun, Jiarui Xiao, Xiaolin Xu, Susanna C. Larsson, Shuai Yuan, Xue Li
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity
    Mohamed Asrih, Flore Sinturel, Richard Dubos, Idris Guessous, Zoltan Pataky, Charna Dibner, François R Jornayvaz, Karim Gariani
    Endocrine Connections.2022;[Epub]     CrossRef
  • Raised circulating soluble growth differentiation factor 15 is negatively associated with testosterone level in hypogonadic men with type 2 diabetes
    Yufeng Mei, Yongnan Lyu, Juan Le, Di Li, Hang Liu, Zhiming Zhao, Yan Li
    Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
  • NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice
    Matthew J Jennings, Alexia Kagiava, Leen Vendredy, Emily L Spaulding, Marina Stavrou, Denisa Hathazi, Anika Grüneboom, Vicky De Winter, Burkhard Gess, Ulrike Schara, Oksana Pogoryelova, Hanns Lochmüller, Christoph H Borchers, Andreas Roos, Robert W Burges
    Brain.2022; 145(11): 3999.     CrossRef
  • Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure
    Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Athanasios Alexiou, Marios Papadakis, Eman Hassan Nadwa, Sarah M. Albogami, Mohammed Alorabi, Hebatallah M. Saad, Gaber El‐Saber Batiha
    Journal of Diabetes.2022; 14(12): 806.     CrossRef
  • GDF15 is an exercise-induced hepatokine regulated by glucagon and insulin in humans
    Peter Plomgaard, Jakob S. Hansen, Logan K. Townsend, Anders Gudiksen, Niels H. Secher, Jens O. Clemmesen, Rene K. Støving, Jens P. Goetze, David C. Wright, Henriette Pilegaard
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • A study of serum growth differentiation factor 15 in Indian women with and without gestational diabetes mellitus in the third trimester of pregnancy and its association with pro-inflammatory markers and glucose metabolism
    Sudipta Banerjee, Rana Bhattacharjee, Amitabh Sur, Pieu Adhikary, Subhankar Chowdhury
    Diabetology International.2021; 12(3): 254.     CrossRef
  • Growth Differentiation Factor 15 is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness
    Yea Eun Kang, Jin Man Kim, Mi Ae Lim, Seong Eun Lee, Shinae Yi, Jung Tae Kim, Chan Oh, Lihua Liu, Yanli Jin, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Jeong Ho Lee, Hyun Jung Kim, Hyun Yong Koh, Sangmi Jun, Sun Wook Cho, Minho Shong, Bon Seok Koo
    Thyroid.2021; 31(5): 772.     CrossRef
  • The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?
    Samuel N. Breit, David A. Brown, Vicky Wang-Wei Tsai
    Annual Review of Physiology.2021; 83(1): 127.     CrossRef
  • Associations of GDF-15 and GDF-15/adiponectin ratio with odds of type 2 diabetes in the Chinese population
    Xiaoying Wu, Wenting Xuan, Lili You, Hong Lian, Feng Li, Xiaoyun Zhang, Qingyu Chen, Kan Sun, Chaogang Chen, Mingtong Xu, Yan Li, Li Yan, Xiuwei Zhang, Meng Ren
    Endocrine.2021; 72(2): 423.     CrossRef
  • Decreased serum growth differentiation factor 15 levels after lifestyle intervention in patients with newly diagnosed type 2 diabetes mellitus
    Xingxing He, Jiaorong Su, Xiaojing Ma, Jingyi Lu, Yufei Wang, Jun Yin, Yuqian Bao, Gang Hu, Jian Zhou
    Obesity Medicine.2021; 24: 100345.     CrossRef
  • The anti-diabetic effects of NAG-1/GDF15 on HFD/STZ-induced mice
    Pattawika Lertpatipanpong, Jaehak Lee, Ilju Kim, Thomas Eling, Seung Yeon Oh, Je Kyung Seong, Seung Joon Baek
    Scientific Reports.2021;[Epub]     CrossRef
  • The Regulation of Circulating Hepatokines by Fructose Ingestion in Humans
    Michael M Richter, Peter Plomgaard
    Journal of the Endocrine Society.2021;[Epub]     CrossRef
  • GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
    Dongdong Wang, Emily A. Day, Logan K. Townsend, Djordje Djordjevic, Sebastian Beck Jørgensen, Gregory R. Steinberg
    Nature Reviews Endocrinology.2021; 17(10): 592.     CrossRef
  • High Fat, High Sugar Diet and DJOS Bariatric Surgery Influence Plasma Levels of Fetuin-B, Growth Differentiation Factor-15, and Pentraxin 3 in Diet-Induced Obese Sprague–Dawley Rats
    Jakub Poloczek, Monika Tarnawska, Elżbieta Chełmecka, Piotr Łaszczyca, Janusz Gumprecht, Dominika Stygar
    Nutrients.2021; 13(10): 3632.     CrossRef
  • Serum growth differentiation factor 15 level is associated with muscle strength and lower extremity function in older patients with cardiometabolic disease
    Kazuhito Oba, Joji Ishikawa, Yoshiaki Tamura, Yasunori Fujita, Masafumi Ito, Ai Iizuka, Yoshinori Fujiwara, Remi Kodera, Ayumi Toba, Kenji Toyoshima, Yuko Chiba, Seijiro Mori, Masashi Tanaka, Hideki Ito, Kazumasa Harada, Atsushi Araki
    Geriatrics & Gerontology International.2020; 20(10): 980.     CrossRef
  • Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach
    Axel C. Carlsson, Christoph Nowak, Lars Lind, Carl Johan Östgren, Fredrik H. Nyström, Johan Sundström, Juan Jesus Carrero, Ulf Riserus, Erik Ingelsson, Tove Fall, Johan Ärnlöv
    Upsala Journal of Medical Sciences.2020; 125(1): 37.     CrossRef
  • Elevated Plasma Growth and Differentiation Factor 15 Is Associated With Slower Gait Speed and Lower Physical Performance in Healthy Community-Dwelling Adults
    Richard D Semba, Marta Gonzalez-Freire, Toshiko Tanaka, Angelique Biancotto, Pingbo Zhang, Michelle Shardell, Ruin Moaddel, Luigi Ferrucci, Anne Newman
    The Journals of Gerontology: Series A.2020; 75(1): 175.     CrossRef
  • Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review
    Alexander E. Berezin, Alexander A. Berezin
    Diabetes Therapy.2020; 11(6): 1271.     CrossRef
  • Deterioration of Sleep Quality According to Glycemic Status
    Myung Haeng Hur, Mi-Kyoung Lee, Kayeon Seong, Jun Hwa Hong
    Diabetes & Metabolism Journal.2020; 44(5): 679.     CrossRef
  • Effects of plant and animal high protein diets on immune-inflammatory biomarkers: A 6-week intervention trial
    Mariya Markova, Liselot Koelman, Silke Hornemann, Olga Pivovarova, Stephanie Sucher, Juergen Machann, Natalia Rudovich, Ralph Thomann, Rosemarie Schneeweiss, Sascha Rohn, Andreas F.H. Pfeiffer, Krasimira Aleksandrova
    Clinical Nutrition.2020; 39(3): 862.     CrossRef
  • Effect of sleeve gastrectomy on plasma growth differentiation factor-15 (GDF15) in human
    Ponnie Robertlee Dolo, Libin Yao, Peng Peng Liu, Jason Widjaja, Song Meng, Chao Li, Xiaocheng Zhu
    The American Journal of Surgery.2020; 220(3): 725.     CrossRef
  • Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers
    Alexander E. Berezin
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(2): 995.     CrossRef
  • Effect of bariatric surgery on plasma GDF15 in humans
    Maximilian Kleinert, Kirstine N. Bojsen-Møller, Nils B. Jørgensen, Maria S. Svane, Christoffer Martinussen, Bente Kiens, Jørgen F.P. Wojtaszewski, Sten Madsbad, Erik A. Richter, Christoffer Clemmensen
    American Journal of Physiology-Endocrinology and Metabolism.2019; 316(4): E615.     CrossRef
  • Regulation of Systemic Glucose Homeostasis by T Helper Type 2 Cytokines
    Yea Eun Kang, Hyun Jin Kim, Minho Shong
    Diabetes & Metabolism Journal.2019; 43(5): 549.     CrossRef
  • GDF15 reflects beta cell function in obese patients independently of the grade of impairment of glucose metabolism
    M.H. Schernthaner-Reiter, B.K. Itariu, M. Krebs, M. Promintzer-Schifferl, T.M. Stulnig, A. Tura, C.H. Anderwald, M. Clodi, B. Ludvik, G. Pacini, A. Luger, G. Vila
    Nutrition, Metabolism and Cardiovascular Diseases.2019; 29(4): 334.     CrossRef
  • Growth differentiation factor 15: A novel biomarker with high clinical potential
    Stéphanie Desmedt, Valérie Desmedt, Leen De Vos, Joris R. Delanghe, Reinhart Speeckaert, Marijn M. Speeckaert
    Critical Reviews in Clinical Laboratory Sciences.2019; 56(5): 333.     CrossRef
  • Hepatokines—a novel group of exercise factors
    Cora Weigert, Miriam Hoene, Peter Plomgaard
    Pflügers Archiv - European Journal of Physiology.2019; 471(3): 383.     CrossRef
  • Association between MIC-1 and Type 2 Diabetes: A Combined Analysis
    Jianan Lu, Yue Zhang, Xingxuan Dong, Jiawen Lu, Chen Zhang, Jieyu Liu, Qingzhou Yu, Haoyue Teng, Qingkui Yao, Jieyun Yin, Liqiang Qin
    Disease Markers.2019; 2019: 1.     CrossRef
  • The mitochondrial unfolded protein response and mitohormesis: a perspective on metabolic diseases
    Hyon-Seung Yi, Joon Young Chang, Minho Shong
    Journal of Molecular Endocrinology.2018; 61(3): R91.     CrossRef
  • Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases
    Ana Luisa Cardoso, Adelaide Fernandes, Juan Antonio Aguilar-Pimentel, Martin Hrabě de Angelis, Joana Ribeiro Guedes, Maria Alexandra Brito, Saida Ortolano, Giovambattista Pani, Sophia Athanasopoulou, Efstathios S. Gonos, Markus Schosserer, Johannes Grilla
    Ageing Research Reviews.2018; 47: 214.     CrossRef
  • Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes
    Ju Hee Lee, Yea Eun Kang, Ji Min Kim, Sorim Choung, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku
    Diabetes Research and Clinical Practice.2018; 135: 7.     CrossRef
  • Growth differentiation factor 15 predicts advanced fibrosis in biopsy‐proven non‐alcoholic fatty liver disease
    Bo Kyung Koo, Sung Hee Um, Dong Soo Seo, Sae Kyung Joo, Jeong Mo Bae, Jeong Hwan Park, Mee Soo Chang, Jung Ho Kim, Jieun Lee, Won‐Il Jeong, Won Kim
    Liver International.2018; 38(4): 695.     CrossRef
  • Serum Growth Differentiation Factor 15 in Parkinson Disease
    Xiaomei Yao, Dong Wang, Lei Zhang, Lingling Wang, Zhenxiang Zhao, Si Chen, Xiaotang Wang, Tao Yue, Yiming Liu
    Neurodegenerative Diseases.2017; 17(6): 251.     CrossRef
  • GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury
    Hyo Kyun Chung, Jung Tae Kim, Hyeon-Woo Kim, Minjoo Kwon, So Yeon Kim, Minho Shong, Koon Soon Kim, Hyon-Seung Yi
    Scientific Reports.2017;[Epub]     CrossRef
  • Growth differentiation factor 15 as a predictor of adverse renal outcomes in patients with immunoglobulin A nephropathy
    Ki R. Na, Yoo H. Kim, Hyo K. Chung, Min‐Kyung Yeo, Young R. Ham, Jin Y. Jeong, Koon S. Kim, Kang W. Lee, Dae E. Choi
    Internal Medicine Journal.2017; 47(12): 1393.     CrossRef
  • GDF15 contributes to radiation-induced senescence through the ROS-mediated p16 pathway in human endothelial cells
    Hyejin Park, Chun-Ho Kim, Jae-Hoon Jeong, Myungjin Park, Kwang Seok Kim
    Oncotarget.2016; 7(9): 9634.     CrossRef
  • GDF-15 and Hepcidin Levels in Nonanemic Patients with Impaired Glucose Tolerance
    Mehmet Muhittin Yalcin, Alev Eroglu Altinova, Mujde Akturk, Ozlem Gulbahar, Emre Arslan, Damla Ors Sendogan, Ilhan Yetkin, Fusun Balos Toruner
    Journal of Diabetes Research.2016; 2016: 1.     CrossRef
  • Cardiac‐Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers
    Colleen M. Dewey, Kathryn M. Spitler, Jessica M. Ponce, Duane D. Hall, Chad E. Grueter
    Journal of the American Heart Association.2016;[Epub]     CrossRef
  • Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study
    Serdar Farhan, Matthias K. Freynhofer, Ivan Brozovic, Veronika Bruno, Birgit Vogel, Ioannis Tentzeris, Sabina Baumgartner-Parzer, Kurt Huber, Alexandra Kautzky-Willer
    Cardiovascular Diabetology.2016;[Epub]     CrossRef
  • Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia
    Ji Min Kim, Min Kyung Back, Hyon-Seung Yi, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku
    Diabetes & Metabolism Journal.2016; 40(1): 70.     CrossRef
  • Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
    Min Young Shin, Ji Min Kim, Yea Eun Kang, Min Kyeong Kim, Kyong Hye Joung, Ju Hee Lee, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong
    Journal of Korean Medical Science.2016; 31(9): 1413.     CrossRef
  • Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose
    Ying Cui, Wen Chen, Jinfeng Chi, Lei Wang
    Medical Science Monitor.2016; 22: 4699.     CrossRef
  • Letter: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J2014;38:472-9)
    Bo Kyung Koo
    Diabetes & Metabolism Journal.2015; 39(1): 82.     CrossRef
  • Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment
    Jun Hwa Hong, Yeon-Kyung Choi, Byong-Keol Min, Kang Seo Park, Kayeon Seong, In Kyu Lee, Jung Guk Kim
    Diabetes Research and Clinical Practice.2015; 109(1): 64.     CrossRef
  • Response: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J2014;38:472-9)
    Jun Hwa Hong, Bon Jeong Ku, Minho Shong
    Diabetes & Metabolism Journal.2015; 39(1): 84.     CrossRef
  • Is GDF15 a Novel Biomarker to Predict the Development of Prediabetes or Diabetes?
    Kyu Yeon Hur
    Diabetes & Metabolism Journal.2014; 38(6): 437.     CrossRef
Is the Indicator Magnifying Window for Insulin Pens Helpful for Elderly Diabetic Patients?
Ju Hee Lee, Eun Shil Hong, Jung Hun Ohn, Young Min Cho
Diabetes Metab J. 2013;37(2):149-151.   Published online April 16, 2013
DOI: https://doi.org/10.4093/dmj.2013.37.2.149
  • 3,300 View
  • 30 Download
AbstractAbstract PDFPubReader   

Patients with type 2 diabetes who require insulin therapy are commonly elderly and have poor visual acuity. In this study, we examined the clinical usefulness of the indicator magnifying window (IMW) for elderly patients with type 2 diabetes. We recruited 50 patients with type 2 diabetes over the age of 60 who had used insulin pens for glucose control. They were asked to set the insulin pen at randomly selected doses with or without an IMW. We assessed dosing accuracy, convenience, self-confidence, need for eyeglasses, preference, and willingness to recommend the IMW to other patients. Although the IMW did not improve the dosing accuracy or convenience, it significantly decreased the need for eyeglasses. Overall, the clinical usefulness of the IMW is quite limited in elderly patients with type 2 diabetes.

Bone Mineral Density in Prediabetic Men (Korean Diabetes J 2010;34:294-302)
Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
Korean Diabetes J. 2010;34(6):386-387.   Published online December 31, 2010
DOI: https://doi.org/10.4093/kdj.2010.34.6.386
  • 3,008 View
  • 29 Download
PDFPubReader   
Bone Mineral Density in Prediabetic Men
Ju Hee Lee, Yun Hyeong Lee, Kyoung Hye Jung, Min Kyeong Kim, Hye Won Jang, Tae Kyun Kim, Hyun Jin Kim, Young Suk Jo, Minho Shong, Tae Yong Lee, Bon Jeong Ku
Korean Diabetes J. 2010;34(5):294-302.   Published online October 31, 2010
DOI: https://doi.org/10.4093/kdj.2010.34.5.294
  • 4,556 View
  • 30 Download
  • 12 Crossref
AbstractAbstract PDFPubReader   
Background

There are many studies regarding the effects of insulin on bone metabolism and changes in bone mineral density (BMD) in the setting of diabetes. The effect of prediabetes on BMD is not known.

Methods

A total of 802 men participated in the Korea Rural Genomic Cohort Study (in Geumsan County). According to the results of an oral glucose tolerance test, subjects were classified into normal, prediabetic, and diabetic categories. One hundred twenty-four subjects diagnosed with type 2 diabetes were excluded, leaving 678 subjects for the study inclusion. BMD was estimated with a quantitative ultrasonometer.

Results

The average BMD T scores of normal and prediabetic subjects were -1.34 ± 1.42 and -1.33 ± 1.30, respectively; there was no significant difference in the BMD T scores between these groups. The BMD T score was inversely associated with age and positively correlated with body weight, body mass index, total cholesterol, low density lipoprotein cholesterol, and HbA1c. On multiple linear regression analysis, low density lipoprotein cholesterol was the only statistically significant variable for prediabetes (β = 0.007, P = 0.005). On the stepwise regression analysis, age (β = -0.026, P < 0.001), the body mass index (β = 0.079, P < 0.001), and low density lipoprotein cholesterol (β = 0.004, P = 0.016) were significant variables for prediabetes.

Conclusions

There was no significant difference in the BMD T score between the normal and prediabetic subjects. Further studies are needed regarding the association of fracture risk and changes in BMD with the development of overt diabetes.

Citations

Citations to this article as recorded by  
  • More Rapid Bone Mineral Density Loss in Older Men With Diabetes: The Osteoporotic Fractures in Men (MrOS) Study
    Flavia Tramontana, Nicola Napoli, Stephanie Litwack-Harrison, Douglas C Bauer, Eric S Orwoll, Jane A Cauley, Elsa S Strotmeyer, Ann V Schwartz
    The Journal of Clinical Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • Prediabetes and skeletal health
    Catherine Lindsay, Albert Shieh
    Current Opinion in Endocrinology, Diabetes & Obesity.2023; 30(4): 200.     CrossRef
  • Serum levels of sclerostin in prediabetes and its correlation with bone mineral density
    Ajay Chauhan, Manoj Kumar Bhakhar, Parul Goyal
    Journal of Family Medicine and Primary Care.2023; 12(11): 2702.     CrossRef
  • The risk of hip fractures in individuals over 50 years old with prediabetes and type 2 diabetes – A longitudinal nationwide population-based study
    Ho Youn Park, Kyoungdo Han, Youngwoo Kim, Yoon Hwan Kim, Yoo Joon Sur
    Bone.2021; 142: 115691.     CrossRef
  • Bone health in diabetes and prediabetes
    Silvia Costantini, Caterina Conte
    World Journal of Diabetes.2019; 10(8): 421.     CrossRef
  • Bone mineral density in obese children with prediabetes
    Ala ÜSTYOL, Mehmet Emre ATABEK
    Ege Tıp Dergisi.2018; 57(2): 94.     CrossRef
  • The Prevalence of Osteopenia and Osteoporosis Among Malaysian Type 2 Diabetic Patients Using Quantitative Ultrasound Densitometer
    Shaymaa Abdalwahed Abdulameer, Mohanad Naji Sahib, Syed Azhar Syed Sulaiman
    The Open Rheumatology Journal.2018; 12(1): 50.     CrossRef
  • An association between bone mineral density and anabolic hormones in middle-aged and elderly men with prediabetes
    Michał Rabijewski, Lucyna Papierska, Paweł Piątkiewicz
    The Aging Male.2017; : 1.     CrossRef
  • Amplification of transcutaneous and percutaneous bone-conduction devices with a test-band in an induced model of conductive hearing loss
    Marn Joon Park, Jae Ryung Lee, Chan Joo Yang, Myung Hoon Yoo, In Suk Jin, Chi Ho Choi, Hong Ju Park
    International Journal of Audiology.2016; 55(11): 653.     CrossRef
  • Osteoporosis in Men with Diabetes Mellitus
    Claire Issa, Mira S. Zantout, Sami T. Azar
    Journal of Osteoporosis.2011; 2011: 1.     CrossRef
  • Response: Bone Mineral Density in Prediabetic Men (Korean Diabetes J 2010;34:294-302)
    Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
    Korean Diabetes Journal.2010; 34(6): 386.     CrossRef
  • Letter: Bone Mineral Density in Prediabetic Men (Korean Diabetes J 2010;34:294-302)
    Chul-Hee Kim
    Korean Diabetes Journal.2010; 34(6): 384.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer